Gilead Sciences Inc. (NASDAQ:GILD) finished Thursday with a subtraction of -$0.71 to close at $76.33, a downside of -0.92 percent. An average of 5,719,220 shares of common stock have been traded in the last five days. There was a fall of -$0.17 in the past week, and it reached a new high 26 times over the past 12 months. The last 20 days have seen an average of 5,421,010 shares traded, while the 50-day average volume stands at 5,770,316.
GILD stock has decreased by -1.11% in the last month. The company shares reached their 1-month lowest point of $75.10 on 08/01/23. With the stock rallying to its 52-week high on 01/06/23, shares of the company touched a low of $61.44 and a high of $89.74 in 52 weeks. It has reached a new high 3 times so far this year and lost -11.09% or -$9.52 in price. In spite of this, the price is down -14.94% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GILD stock investors should be aware that Gilead Sciences Inc. (GILD) stock had its last reported insider trading activity 36 days ago on Jul 20. In this transaction, the insider spent $400,000. Chief Medical Officer, Parsey Merdad, disposed of 1,485 shares at a price of $76.90 on Jun 13. The insider now owns more than $114,197 worth of shares. Prior to that, Chief Medical Officer Parsey Merdad went on to Sale 6,126 shares at $78.99 each on Mar 13. An amount of $483,893 was transacted.
Valuation Metrics
Gilead Sciences Inc. (GILD) has a trailing price-to-earnings (P/E) ratio of 17.56. The stock’s beta is 0.38. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.50, the price-to-book (PB) ratio at 4.51, and the price-to-cash flow ratio at 10.74.
Financial Health
The quick ratio of Gilead Sciences Inc. for the three months ended June 29 was 0.90, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.00 and a total debt to equity ratio of 1.19 for the quarter ending June 29. Gilead Sciences Inc.’s EBITDA margin for the year ending June 29 is 47.48%, while its operating margin for the same period stands at 30.90%. Its gross profit as reported stood at $21.62 billion compared to revenue of $27.28 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Gilead Sciences Inc.’s return on assets was 8.80%.
Earnings Surprise
For the three-month period that ended June 29, Gilead Sciences Inc. had $21.21 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.04 billion in the quarter, while revenues were shrunk -9.47%. The analyst consensus anticipated Gilead Sciences Inc.’s latest quarter earnings to come in at $1.64 per share, but it turned out to be $1.34, a -18.30% surprise. For the quarter, EBITDA amounted to $2.35 billion. Shareholders own equity worth $1.25 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Gilead Sciences Inc. (GILD) price momentum. RSI 9-day as of the close on 24 August was 39.23%, suggesting the stock is Neutral, with historical volatility in this time frame at 14.71%.
As of today, GILD’s price is $76.31 -0.22% or -$0.17 from its 5-day moving average. GILD is currently trading -0.24% lower than its 20-day SMA and -8.00% lower than its 100-day SMA. However, the stock’s current price level is -2.70% below the SMA50 and -4.99% below the SMA200.
The stochastic %K and %D were 20.84% and 18.31%, respectively, and the average true range (ATR) was 1.62. With the 14-day stochastic at 15.98% and the average true range at 1.59, the RSI (14) stands at 42.87%. The stock has reached -0.71 on the 9-day MACD Oscillator while the 14-day reading was at -1.74.
Analyst Ratings
Barclays reiterated its an Equal weight rating on Gilead Sciences Inc. (NASDAQ: GILD), but raised their price target to $81, indicating a potential price increase of 5.77% for the stock. The consensus rating for Gilead Sciences Inc. (GILD) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell GILD, while 16 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 13 others rate it as a “buy”.
What is GILD’s price target for the next 12 months?
Analysts predict a range of price targets between $80.00 and $116.00, with a median target of $90.00. Taking a look at these predictions, the average price target given by analysts for Gilead Sciences Inc. (GILD) stock is $91.23.
